Method for treating solid tumors by means of topical and injectable administration of carbon-containing small-molecule compound

Abstract

A carbon-containing small-molecule compound (referred to as CKM) for treating cancer via topical or injectable administration. Ingredients of the extract include eugenol and syringyl alcohol.

Description

A method for treating cancer with a small carbon element-containing compound composition for external use and injection

[0001] Although drugs have therapeutic effects on diseases, almost all cancer drugs produce many drug toxic side effects during treatment. These side effects significantly reduce the immunity of cancer patients and have undeniable immediate or long-term adverse effects on patients, severely weakening the clinical therapeutic effect of cancer drugs. The damage of cancer drugs to normal cells and the damage to the immune system cannot be ignored. How to minimize drug toxic side effects while achieving drug efficacy to maximize the efficacy of cancer drugs is the most difficult and most overlooked challenge in cancer drug research.

[0002] Cancer is a pathological phenomenon of abnormal cell proliferation, spread, and metastasis caused by physiological mechanism disorders and cells not being regulated by genes, biological information, and immunity. Abnormal cells not regulated by normal biological immune mechanisms are cancer cells, and uncontrolled cell proliferation is malignant cancer tumors. The malignant solid tumors generated by cancer cells are the most intuitive markers of most cancers. Cancer cells and malignant tumors can occur in any part of the human body and organ tissue. According to the part where cancer cells and malignant tumors occur, different cancer names such as brain cancer, liver cancer, lung cancer, stomach cancer, thymus cancer, pancreatic cancer, nasopharyngeal cancer, laryngeal cancer, bladder cancer, uterine cancer, colon cancer, bone cancer, and blood cancer are given. The site and morphology of cancer cells and various solid malignant cancer tumors generated are not entirely the same, but they all have the common pathological basis of uncontrolled excessive cell proliferation and variation. Cancer cells are not easy to detect and spread quickly, so most malignant cancer tumors are discovered when patients are already in the advanced or terminal stage of cancer. In the advanced or terminal stage of cancer, most drugs and treatment speeds cannot keep up with the speed of cancer cell proliferation and spread, making it more difficult to control the growth of cancer cells and cancer tumors. The secondary damage and repeated damage of drugs to normal cells and the immune system during cancer treatment accelerate the decline of the immune system of cancer patients, making their appetite worse, nutritional intake worse, spirit worse, sleep worse, weight loss, and physical strength continuously weakened, making the patient's quality of life and immunity more rapidly decreased and the spirit more rapidly increased.

[0003] Improving the clinical therapeutic effect of cancer drugs and reducing the damage of drug toxic side effects to normal cells, inhibiting the spread and metastasis of cancer cells, preventing the spread of cancer cells, eliminating cancer pain, improving self-anti-cancer immunity, and improving the survival and survival of patients are the problems that should be studied and overcome.

[0004] Pharmacological theory generally believes that the drug effect of skin drug administration on internal organ diseases is much slower and inferior to oral and injection drug administration due to the physiological barrier effect of the skin. The skin drug treatment of internal organ diseases It is a common knowledge in the medical field that the onset time and effect of transdermal administration are generally lower than those of oral and injection administration. There is no report on a cancer treatment drug that can kill cancer cells, inhibit tumor growth, eliminate tumor, prevent cancer cell proliferation and metastasis, and not harm normal cells and immune system, and can prolong the survival period of cancer patients and improve the quality of life. ABSTRACT

[0005] All cancers have their own different cancer markers and detection methods, but the main detection standards are the size of solid tumor, related specific cancer markers, patient survival time, and pathological indicators. Although cancers occur in different organs and body parts, they all have the commonality of uncontrolled cell proliferation and spread due to abnormal cell apoptosis mechanism. Cancer treatment methods include radiation, electrotherapy, chemotherapy, targeted drugs, oral drugs, and injection, etc. However, all treatment methods and drugs cause different degrees of secondary damage and repeated harm to normal cells and immune system while treating cancer or killing cancer cells, and produce many side effects (such as hair loss, reduced immunity, weight loss, vomiting, etc.). In the process of cancer treatment, normal cells are repeatedly damaged by drugs, which greatly damages the physical fitness, physical ability, and immunity of patients, greatly reduces the clinical treatment effect, and greatly reduces the survival rate and quality of life of cancer patients. The extremely high cancer mortality rate often makes patients, family members, and doctors feel hopeless.

[0006] To improve the onset rate of treatment drugs, increase drug safety, reduce drug toxic side effects, and reduce damage to normal cells and immune system, the immune function can be restored to help and prevent cancer cell proliferation and metastasis, the tumor growth rate can be truly inhibited, and cancer cells can be truly eliminated, which can truly improve the quality of life and prolong the survival period of cancer patients. Restoring the normal mechanism of immune regulation in cancer patients and mobilizing the body's immunity to inhibit the proliferation of malignant tumors and prevent cancer cell proliferation is a new idea and fundamental treatment method for cancer treatment.

[0007] The present application is a method for treating cancer by using plant carbon element small molecule compound extract for external use and injection. The extract in the present application is referred to as CKM. The CKM can be used for treating internal organ cancer such as liver and thymus by external use and injection, can avoid neutralization and decomposition of drug molecules by oral cavity and gastric juice, can avoid degradation by digestive enzymes, and can overcome the problems of slow onset, poor drug effect, large side effects, and reduced immunity of drugs for treating cancer cell proliferation, malignant tumors, and cancer pain. When killing cancer cells, the CKM has fast onset time, can quickly reduce the size of solid tumors, does not cause secondary damage to normal cells and organ tissues, and can prolong the survival period of cancer patients. And repeated injury, can maintain and enhance the patient's own immunity to cancer, improve the quality of life, prolong survival.

[0008] 本專利發明中 CKM以皮膚外用或注射方式治療癌症，與己知文獻報導臨床療 The method and the drug compared, have fast effect, high absorption and utilization rate and almost no side effects, can produce significant inhibition, tumor, prevent cancer cell proliferation, prevent cancer cell metastasis and spread of therapeutic effect, can balance and enhance the immunity of cancer patients, and avoid secondary and repeated injury of normal cells by drugs. The rate of onset and drug molecular activity and biological effect and drug molecular transmission across the cell membrane and transdermal absorption, multi-target effect and immune regulation are related.

[0009] 本發明中 CKM為小分子態化合提取物皮膚外用及注射，治療包括而不限於內 Organ cancer, with fast onset time, high biological treatment effect and few side effects, can quickly inhibit and kill cancer cells, prevent cancer cell spread and metastasis, and can make cancerous malignant solid tumors shrink and disappear rapidly.

[0010] 本專利發明中 CKM適合以皮膚外用及注射方式治療包括而不限於肝癌等癌 Symptoms, can improve and restore normal immune regulation function, have strong and rapid inhibition and killing effect on cancer cells, and can significantly improve the physical fitness and quality of life of cancer patients, and no side effects have been found. In the present invention, CKM stands for Cancer cell killing micromolecule, which can be a plant extract but also can be obtained by artificial chemical synthesis. The figure simply explains

[0011] As those skilled in the art will appreciate, the elements in the figures are illustrated for simplicity and clarity and can have not all conjoined and selected to appear in the commonly used but well-known elements that are useful or necessary in commercially feasible implementations. It can be further understood that, as those skilled in the art can understand, such specificity in sequence is not actually required. It can also be understood that the terms and phrases used herein are defined in their respective investigation and research fields, unless otherwise specified herein.

[0012] 圖 1為條形圖，顯示一示範例中，CKM經皮膚外用於內臟器質性肝癌患者的 AFP value continues to decrease.

[0013] 圖 2為條形圖，顯示在一示範例中，裸鼠經皮膚外用 CKM後第 12日、21日 Internal organ quality liver cancer solid tumor atrophy.

[0014] 圖 3條形圖顯示，顯示一示範例中，裸鼠動物實驗經皮膚外用 CKM後第 26 The internal organ quality liver cancer solid tumor continues to shrink significantly within 30 days.

[0015] 圖 4為條形圖顯示，顯示一示範例中，大鼠動物一次性皮膚外用 CKM 2500mg / kg large dose (far more than the human treatment dose) acute toxicity experiment, no difference between the body weight of experimental animals in each group, showing that CKM has no acute toxicity response at 2500mg / kg large dose.

[0016] 圖 5為一表格，顯示大鼠承天液克癌靈經皮膚染毒後的體重變化。

[0017] 圖 6為一表格，顯示所有動物取血進行血液分析與解剖內臟檢測報告。

[0018] 圖 7為一表格，顯示為血液生化檢查項目報告。

[0019] 圖 8為一表格，顯示為血液生化檢測報告。

[0020] 圖 9為一表格，顯示為動物食物消耗量報告。

[0021] 圖 10為一表格，顯示解剖後臟器係數報告。

[0022] Detailed description

[0023] 在本專利發明一實施例中，以 CKM皮膚外用人體幫助癌患者抑瘤、消除癌症Pain, recovery of activity, prolongation of life and improvement of quality of life. In an embodiment of the present invention, the CKM treatment of cancer by external application to the skin of animals supports the implementation of anticancer, tumor elimination, killing of cancer cells, prevention of cancer cell proliferation and metastasis. In an embodiment of the present invention, the CKM helps the treatment of end-stage thymus cancer patients, tumor suppression, elimination of chemotherapy sequelae and improvement of quality of life through external application to the skin. In an embodiment of the present invention, the CKM helps end-stage liver cancer patients to recover their activity, treat cancer pain and prolong their life through external application to the skin. In an embodiment of the present invention, the CKM injection into animals supports the treatment effect of CKM on the suppression of cancer, tumor elimination, prevention of cancer cell proliferation and metastasis of parenchymal liver cancer. In an embodiment of the present invention, through large-dose acute toxicity experiments on animals, it is supported that CKM has no side effects on normal cells and organ tissues. In an embodiment of the present invention, through 30-day subacute toxicity experiments on animals, it is supported that CKM has no side effects on normal cells and organ tissues. In summary, CKM has a rapid and obvious drug treatment effect on cancers including but not limited to liver cancer through external application to the skin or injection, and can significantly improve or eliminate the sequelae produced by chemical drug treatment. The present invention proves that whether CKM is used for one-time or long-term treatment of cancer, in addition to the obvious effect of killing cancer cells and shrinking cancer tumors, no other side effects and damage to normal cells or organs are found.

[0024] 本專利是用 CKM以皮膚外用或注射方式治療包括而不限於內臟器質性癌症的 The present invention, CKM, in the implementation of tumor suppression, tumor elimination, killing of cancer cells and relief of cancer pain, avoids secondary and repeated damage to normal cells during cancer treatment, improves the sequelae produced by other chemical drug treatment, significantly improves the normal immune ability of the human body, and improves the quality of life and life expectancy of cancer patients.

[0025] This patented invention believes that living things (including humans, animals, plants, and microorganisms) are carbon-based life forms. Because the amino and carboxyl groups of amino acids in carbon-based organisms are connected by carbon elements, some small molecule compounds containing carbon elements are also more easily recognized by cells due to their small molecular weight, high molecular density, and high biocompatibility. Under certain conditions, they are also prone to produce biochemical and physiological reactions with certain cells. Therefore, the carbon-containing element CKM can pass through the skin through free diffusion and non-voltage-gated ion channels across the biological cell membrane and enter cancer cells. By balancing and regulating immunity, it promotes the body to produce anti-cancer and anti-cancer biological activities, which can strongly inhibit the proliferation and spread of tumor cells. Although some biological effects produced between CKM and biological cells in the present invention have yet to be discovered and studied, it is undeniable that in the present invention, CKM, whether applied externally or injected through the skin, has shown significant and effective drug therapeutic effects on cancer cells and tumors in animals or humans, and has also produced a regulatory and balancing effect on immune cells and immunity within a visible range, thereby showing a significant inhibitory and killing effect on malignant tumors and cancer cells. Its mechanism of action is related to a series of biological reactions such as the participation of polyphenolic carbon-containing small molecules in information transmission between biological cells, amino acid sequence restoration, protein structure restoration, cell function expression and immune regulation mechanism.

[0026] This patented invention believes that there are close physiological and cellular micro-information transmission connections between organisms, between organisms and the environment, between cells, and between molecules. This connection is established or presented through different means such as DNA, mRNA, bioelectric currents, neurons, ion channels, meridians, energy fields, biopotentials, touch, and perception. When the micro-information transmission in these microenvironments is unbalanced, errors may occur in any micro-node or micro-space structure, which may lead to abnormal cell apoptosis mechanisms and cause cancer.

[0027] This patented invention believes that life lies in movement. All cells and organs in a living body are in a relatively dynamic physiological balance. This balance is not an absolute and unchanging balance but a dynamic relative balance that changes every second. Dynamic homeostasis is the core of living organisms' health and the normal functioning and survival of cells. It also serves as the mechanism for normal cell apoptosis. This non-absolute dynamic equilibrium maintains the normal functioning and continuation of life. When any external or endogenous factors (such as artificial chemicals) disrupt this delicate dynamic balance within the living space, abnormal pathological phenomena can occur in the cells and organs of living organisms, prompting cell proliferation and the development of cancer. The proliferation and spread of cancer cells, uncontrolled by the biological information of living organisms, weakens normal immunity, contributing to the high cancer mortality rate.

[0028] The patent invention believes that the skin is the largest organ and the largest physiological barrier of the human body and other animals. The skin separates most harmful substance molecules and also separates most drug molecules, making it difficult for them to enter the body from the skin. Most drug components cannot pass through the epidermis and dermis from the skin to enter the internal organs, making it extremely difficult for most drugs to have a drug treatment effect on internal organ cancer.

[0029] 本專利發明中 CKM經皮膚外用而對體內器官癌症產生治療作用其含碳原子及 One of the reasons is that the compound molecule is small. Carbon element with atomic weight 12.011 is a small molecular substance that is stable at room temperature, but since humans belong to carbon-based organisms and all carbon-based organisms have common characteristics that can be affected by external wind, cold, dry, heat, wet physical and artificially synthesized substances, etc. Therefore, in this invention, the CKM lipid-soluble characteristics and the small-molecule polyphenol active characteristics can easily enter the body through the skin in a free movement, non-voltage-gated ion channel, and other transmembrane ways to produce regulatory effects on immune cells, and can intervene in cancer cell tissue to quickly bind to cancer cells, inhibit the rapid proliferation and spread of cancer cells, and the inhibition and killing of cancer cells are one of the reasons for the rapid effect of CKM to produce clinical treatment drug effects.

[0030] 本專利發明中 CKM經皮膚外用或注射具有維持及恢復免疫機制抑制癌細胞異 The effect of commonly spreading and eliminating malignant tumor proliferation, the target specificity, multi-target and multi-directional inhibition of cancer cell proliferation, prevention of cancer cell spread and elimination of cancer cells without damaging normal cells is one of the drug action mechanisms of this patent invention for treating cancer, preventing cancer recurrence, and enabling cancer patients to maintain normal immunity.

[0031] In this patent invention, it is believed that all therapeutic cancer drugs with toxic side effects and adverse reactions will reduce the immunity of cancer patients, destroy the immune regulation mechanism of cancer patients, destroy the immune stress capacity of cancer patients, and make it impossible to reduce the mortality rate of cancer patients. In this patent invention, the influence of CKM on the immunity of cancer patients and the maximum reduction of drug toxic side effects increase the therapeutic effect of the drug, and the clinical treatment effect and safety presented prove the novelty, practicality and innovation of this invention.

[0032] 在本專利發明中正常的動物及正常人體經皮膚使用治療癌症劑量的 CKM沒有 The discovery of side effects proves that CKM does not damage normal cell tissue, organs and normal immunity of organisms, and shows that CKM is safe and has obvious drug treatment targeting for cancer cells.

[0033] 在本專利發明中 CKM對包括而不限於肝癌的其它癌症也具有同樣治療效果， It shows that CKM has a broad-spectrum treatment for cancer in different organ tissues.

[0034] 在本專利發明中經大鼠動物急毒實驗証實 CKM經皮膚一次性使用的最大耐受 The dose is >2500m / kg, which is much larger than the actual treatment dose of the human body, belongs to the actual non-toxic level, and shows the dual advantages of effectiveness and safety of CKM.

[0035] 在本專利發明中經豚鼠 30日動物亞急毒實驗証實，其經皮膚使用 30日（每 1mL and 2mL per day) showed no abnormal reactions or side effects in animals, and the animal experiment results and human use observations showed consistent safety.

[0036] In the present invention, including but not limited to liver, thymus cancer patients skin use certificate, daily effective amount of 3mL-6mL / 60kg / day, no side effects were found, animal toxicology safety test and human use showed no side effects and damage to normal cells, produce therapeutic effect while not damage to normal cells, is one of the unique features of the present invention which is different from other cancer drugs.

[0037] The present invention believes that cancer is a physiological immune balance mechanism disorder and cell uncontrolled apoptosis abnormal cell proliferation, spread and metastasis. The abnormal proliferation of cells that endanger life is cancer cells, and the main pathological marker of cancer is malignant tumor. Although cancer cells and malignant tumors occur in different parts and organ tissues, the pathological phenomena of uncontrolled cell proliferation and immune system destruction are common pathological symptoms of all cancers, and are the same point of all cancers. Various cell variations, proliferation, spread, metastasis and malignant tumor phenomena of various cancers occur in different parts of the body and different organ tissues and are named with different cancer names (such as lung cancer in the lung, liver cancer in the liver, brain cancer in the brain, and nasopharyngeal cancer in the nose). However, they all have the same disease mechanism, which is one of the main pharmacologies of CKM that can produce therapeutic effects and biological effects on cancers including but not limited to liver cancer.

[0038] 在本專利發明中以從特別選擇的植物中具有抑癌、殺癌細胞的 Cancer cell killing micromolecule (CKM) for treating cancer by external use or injection is a kind of skin drug The present invention is a new invention for treating internal organ cancer and malignant tumor with high safety and no side effects.

[0039] 本專利發明中將 CKM以皮膚外用及注射方式治療不同癌症，CKM小微分子特 The sex and transmembrane absorption characteristics make it easy to break through various physiological barriers such as blood-brain and kidney organs, and can completely avoid oral enzyme degradation, gastric acid destruction and liver first-pass effect, and act on cancer cells and tumors in internal organs.

[0040] 本專利發明中以 CKM經皮膚外用治療癌症也能以注射方式施用於內臟器質性 The cancer tumor or corresponding part (including but not limited to abdominal cavity) can effectively kill cancer cells, inhibit tumor proliferation and spread, restore normal immunity and improve the quality of life of patients, mobilize the body's self-healing mechanism to help patients increase survival period and improve quality of life. The present invention supports the effect of CKM in treating and reducing malignant tumors, killing cancer cells, preventing cancer cell spread and metastasis, eliminating pain, prolonging survival and improving quality of life.

[0041] 在本發明中用 CKM以皮膚外用方式施用於經注射嗎啡止痛完全無效的包括而 Not limited to end-stage internal organ cancer patients, with different degrees of obvious tumor inhibition, cancer cell killing and pain relief effects, and can improve the clinical symptoms of cancer including but not limited to end-stage nasopharyngeal cancer nasal cavity ulceration, end-stage lung cancer unable to swallow, voiceless, end-stage colorectal cancer defecation disorder, and bladder cancer.

[0042] 在本發明中 CKM皮膚外用在殺滅癌細胞與阻止癌細胞擴散及轉移同時具有强The analgesic effect is compared with the analgesic effect of injecting morphine in patients with terminal cancer. The analgesic effect is rapid and there are no side effects such as allergy, irritation, addiction, withdrawal, etc. Although various objective reasons limit the regular and rigorous observation and statistics of CKM for cancer analgesia, after non-formal dozens of cases of patients who have no effect after injecting morphine in the past 30 years, it is found that the analgesic effect of CKM is about 3-8 minutes, complete analgesia is about 5-10 minutes, and analgesia lasts for about 4-10 hours. The analgesia improves appetite, sleep, weight and fatigue condition.

[0043] 本專利發明中以 CKM直接外用於皮膚因應不確定包括而不限於其它過敏源與 The drug stimulation and other factors can also produce corresponding effects after being adapted to other substances or properly neutralized and diluted. The molecular weight of CKM in the invention is one of the elements, the skin external use is the second element, the proper proportion of other solvents is the third element, the fat-soluble property is the fourth element, the extended injection is the fifth element, and the combination with other substances is the sixth element.

[0044] 本專利發明中 CKM雖來自於植物基源但也可以人工合成方式取得，這類含碳 The small and micro-molecular compounds and carbon-based life exist in a special field space, and the molecular cross-reaction between them can be complementary. Compared with other drugs and treatment methods, the molecular cross-reaction can be directly transported to the cancer cells in the internal organs through various transmembrane methods such as free diffusion, passive transport and ion channel transport, and can act on cancer cells and telomeres. It can also be transported by blood injection or directly injected into the cancer tumor.

[0045] 本專利發明中 CKM通過參入生物免疫機制生化反應，對內臟器質性癌產生的 The biological effect is one of its unique features. The restoration of cell function through endogenous cell regulation mechanism is the second unique feature. The restoration of biological immune recognition mechanism balance and the restoration of biological self-healing mechanism can achieve the treatment of internal organ cancer.

[0046] 本專利發明中以 CKM皮膚外用治療內臟器質性癌症的方法與其它治療癌症方 Compared with other treatment methods and drugs, the skin external use method is more convenient, faster, safer and more effective. Injection is an extension of the skin external use method and a deeper extension of the skin external use method.

[0047] 本專利發明中因為 CKM皮膚外用與注射方式能避免口腔消化酶、胃酸、肝臟 The first-pass effect and the physiological barrier of blood-brain and kidney organs are the most direct, fastest, least harmful, least harmful to normal cells, and fastest treatment method for cancer. It is also a new immunomodulatory small molecule drug and method.

[0048] 本專利發明中 CKM是組成氨基酸脂肪族、芳香族、氨基酸三大類小分子化合 The composition of the drug can change or affect, regulate, repair protein structure, restore protein spatial structure and functional expression based on the molecular drug theory. The skin external use and the way of including but not limited to abdominal injection can treat internal organ cancer and kill cancer cells, which can fully avoid the damage of oral and gastric acid, avoid gastric juice neutralization and decomposition, and help to quickly remove cancer cells and prolong the survival period of cancer patients.

[0049] 本專利發明中 CKM可以與其它溶媒與稀釋物或配合物等組合使用而稀釋及組The molecular weight of the compound is preferably controlled below 500 daltons, and the molecular weight of the composition is preferably less than 500 daltons, or less than 300 daltons, or even less than 30-230 daltons. The biological effect is better. In theory, other unknown small molecular compounds may increase some adverse reactions if combined with CKM, and different types of small molecular compounds may increase or decrease the biological effect of a single compound.

[0050] 本專利發明中 CKM不排除相同人工合成物也有相同功能效用，人工化合物與 The chiral mirror phenomenon of natural compounds may cause some differences in biological effects or produce reverse phase effects. The differences may be reflected in the rate of molecular entry into cells, the strength of biological effects, and the level of safety, as well as the size of side effects on normal cells, the therapeutic efficacy on cancer cells, and the speed of onset time.

[0051] In this patent invention, the types and amounts of molecular chemical components in physical space and their mutual proportions will change or restore their chemical molecular equilibrium relationship. The ratio between them has an important influence on the balance of molecular functions. The more cross nodes between molecules in the same chemical physical space, the greater the change in quantity. Some new biological effects may be produced between them and other molecular biochemical reactions or electronic replacement reactions, but it is also possible that uncontrollable molecular recombination may produce some other effects.

[0052] 本專利發明中利用 CKM的生物認同性及相容性與排異性以皮膚外用及注射方 The formula regulates the balance of immune mechanisms, restores physiological normal regulation mechanisms, and kills cancer cells. It can present multi-directional, multi-targeted, and multi-functional effects for treating cancer. The functional effects produced are a balance of variables and ratios, and some factors may cause corresponding functional changes.

[0053] The initial stage of the patent invention research process is to use plant-based sources as the screening category range for finding effective ingredients. After a long period of extensive comparative analysis and research, the present invention includes, but is not limited to, the following: ginger (Zingiber officinale), chili pepper (Capsicum annuum), onion (Allium cepa), garlic (Allium sativum), pepper (Piper nigrum), Sichuan pepper (spicy), bergamot (Citrus medica var.), lemon (Citrus limon), orange (Citrus reticulata), green olive (Canarium album) (fruit), Rosa rugosa, lavender (Lavandula), Andropogon zizanioides, Angelica sinensis, Cymbopogon (aromatic oil), chrysanthemum (Cymbopogon), tea flower (Camellia japonica), sweet olive (Osmanthus fragrans) (flower leaf), black fungus (Auricularia auricula), white fungus (Tremella fuciformis), red algae (Rhodophyta) (containing gelatinous substances), ginseng (Panax ginseng), American ginseng (Panax quinquefolius), Codonopsis pilosula, olive (Canarium), Codonopsis pilosula (ginseng material), cucumber (Cucumis sativus), pumpkin (Cucurbita cv), luffa (Luffa aegyptiaca) (melon), eucalyptus leaves (Eucalyptus globules), fennel (Foeniculum vulgare), clove (Eugenia caryophyllata Thunb), Syzygium aromaticum, cinnamon (Cinnamomum cassia), rosemary (Salvia rosmarinus), coriander (Coriandrum sativum), and hundreds of other specially selected plants and extracts.After comparison and repeated screening, it was finally found and identified that plant clove Eugenia caryophyllata Thunb or Syzygium aromaticum or Syringa oblata Lindl extract (including but not limited to eugenol C10H12O2, syringyl alcohol C15H26O) has different degrees of anticancer and cancer pain relief effects by oral and external use. However, it was also found that oral side effects are larger, and the dose-effect relationship of drug efficacy and side effects is positively related.

[0054] 本專利發明中以植物丁香 Eugenia caryophyllata Thunb或 Syzygium After comparison and repeated screening, it was finally found and identified that plant clove Eugenia caryophyllata Thunb or Syzygium aromaticum or Syringa oblata Lindl extract (including but not limited to eugenol C10H12O2, syringyl alcohol C15H26O) has different degrees of anticancer and cancer pain relief effects by oral and external use. However, it was also found that oral side effects are larger, and the dose-effect relationship of drug efficacy and side effects is positively related.

[0055] In this patent invention, whether clove and clove extract or clove extract compound is used as a medicine by oral administration, the biological effect is low, the risk is high, and the safety cannot be fully guaranteed. The side effects increase the risk of decreased immunity, so in this patent, transdermal external use and extended injection are finally adopted.

[0056] 本專利發明在研究過程中發現包括而不限於丁香酚 Eugenol、丁香醇 Clove extract such as syringyl alcohol has the characteristics of fat solubility and small molecular weight. After using it externally and by injection, the anticancer, tumor reduction and pain relief effects are much faster and more significant than oral administration, which supports that transdermal external use and injection are better and safer than oral administration in treatment, and can significantly maintain and improve the immune ability of the present image.

[0057] 本專利發明中將包括而不限於丁香酚 Eugenol、丁香醇 syringyl alcohol的 Clove extract for transdermal external use and injection treatment of various internal organ cancers including but not limited to liver, thymus, etc. has anticancer, tumor reduction and cancer cell killing effects regardless of the length of use, so in this patent invention, clove extract (including but not limited to eugenol and syringyl alcohol) for transdermal external use and injection treatment of internal organ cancers including but not limited to liver, thymus, etc. is named Cancer cell killing micromolecule, abbreviated as CKM.

[0058] 本專利發明中 CKM因當量濃度高不適宜口服，但極適合以皮膚外用及以注射The treatment method includes, but is not limited to, treatment of internal organ cancer. The method can control tumor proliferation, has obvious cancer cell killing and tumor shrinking effects, and can rapidly relieve cancer pain, improve the quality of life of cancer patients, and has corresponding drug treatment effects on internal organ cancer, including but not limited to liver, lung, nasopharynx, colon, bladder, etc. It is found that if CKM is combined with other substances for external use, it also has corresponding biological effects to different degrees, so it is not excluded that it can be widely used in pharmaceuticals and health products.

[0059] 本專利發明中 CKM與其它物質加以包括但不限於稀釋、組合等不同劑量及劑 The health care product, skin care product, and daily health care product can be used for treatment of cancer at any stage. The content is preferably in the range of >10 ppm and <50%, and the specific content and proportion are determined according to the characteristics of the related substances and the use purpose.

[0060] 本專利發明中以 CKM皮膚外用或注射方式治療癌症，對於癌症治療效果與其 Compared with public drug reports and research papers, the method is superior to other treatment methods and drugs, including but not limited to chemotherapy, radiotherapy, electrotherapy, oral drugs, and targeted drugs. It can regulate, promote, and restore normal cell function, inhibit the growth of internal organ cancer, reduce or eliminate the spread of cancer cells, and relieve severe pain caused by syndromes. It can improve the appetite of cancer patients, improve the sleep of cancer patients, improve the mental fatigue of cancer patients, restore the body weight of cancer patients, improve the quality of life of cancer patients, and prolong the survival period of cancer patients.

[0061] 本專利發明中 CKM皮膚外用或注射治療包括但不限於內臟器質性癌症起效迅 The CKM small molecule extract described in the present application can be obtained from plants such as clove, and is not excluded from other plants or artificially synthesized. It includes, but is not limited to, phenolic carbon-containing molecules or eugenol (C10H12O2) and syringyl alcohol (C15H26O). The obtaining method can include, but is not limited to, water boiling concentration, distillation, pressing, evaporation, freezing, chromatography, separation, supercritical, high-pressure spraying, and artificial synthesis.

[0062] 本專利發明中 CKM可以單獨使用或與其它包括而不限於液象、固象及氣象形 The substance can be used in combination, blending, fusion, chelation, coupling, and complexation. The form includes, but is not limited to, wipes, creams, sprays, ointments, patches, and solid forms. The use method includes, but is not limited to, external use or injection, and can be extended to various forms, methods, and combinations for use in pharmaceuticals, health products, and skin care products.

[0063] 本專利發明中所述 CKM無論是單獨還是與其它包括而不限於配合、組合、複 The substance can be used for external use or injection for cancer treatment, but oral or other use methods are not excluded.

[0064] The appropriate dosage and usage method (one or more times a day, each time <15 ml and multiple usage <40 ml) in this patent invention have not found side effects, while inappropriate dosage and usage method may cause skin allergy, nausea, stomach burning, and diarrhea in cancer patients, and these side effects are related to the usage method, usage amount, dilution, and matching ratio of combination factors to varying degrees.

[0065] The common characteristics of abnormal proliferation of cancer cells regardless of biological mechanisms, and the biological effects of CKM on other organic cancers including but not limited to liver cancer, such as tumor suppression, tumor regression, and prevention of cancer cell metastasis and spread, as well as the restoration of normal immunity and the increase of survival period, support the pharmacological commonality of the CKM treatment examples shown, including but not limited to liver, thymus cancer, and other cancers.

[0066] 本專利發明中所述 CKM外用於皮膚與注射或與其它溶劑及物質組合後外用於 The effects and mechanisms of treating cancer by skin and injection methods include but are not limited to protein and amino acid and DNA, mRNA, as well as cell and telomerase and taste, smell, neuron, and other action pathways and mechanism targets, which can be understood as the basis for extending the research of cancer disease mechanism and the development of new cancer drugs and screening platforms, or chips and artificial intelligence AI and four-dimensional computing technology, and also for extending the research and development of new cancer diagnosis and drug screening and clinical treatment methods.

[0067] 本專利發明中所述 CKM與其它溶劑組合外用於皮膚或注射治療癌症在實施例 After dissolving and complexing with other substances (including but not limited to oil, extract, solvent, etc.), the treatment of cancer and the mutual reference ratio of the solvent are preferably 5:5, more preferably 4:6, and the ratio range of 0.5-3.5:6.5-8 is the best.

[0068] 本專利發明中 CKM與任何其它適宜分子或化合物以適當比例組合皮膚外用或 The appropriate combination of injection treatment for cancer can reduce skin irritation and allergy or avoid side effects, and may also improve tumor suppression and tumor regression, kill cancer cells, and relieve pain, increase the effect of preventing cancer cell spread and reducing cancer cell metastasis, and eliminate cancer pain, improve sleep quality, and improve mental state, which does not exclude the contribution of immune mechanism recovery In cancer patients, appetite improvement, immune enhancement, physical improvement, and body weight recovery.

[0069] 本專利發明在一個實施例中支持了 CKM經人體皮膚外用治療與改善末期肝癌 Patients can reduce tumor size and significantly relieve pain, and the alpha-fetoprotein (AFP) index of liver cancer patients can be reduced from 93611 ng / ml to 1072 ng / ml in 90 days, with an improvement of 87.324%, which improves appetite and mental state, improves sleep quality, and restores body weight, showing significant recovery of immunity and improvement of cancer patient survival quality and prolongation of survival period.

[0070] 本專利發明在一個實施例中支持了 CKM經皮膚外用與注射治療裸鼠內臟器質The experimental condition of liver cancer, the significant therapeutic effect on liver tumor can quickly reduce the liver tumor volume without affecting the activity and survival ability, the tumor volume of (1.8 cm3) large tumor was significantly reduced by 63.2% on the 12th day of using CKM, by 70% on the 26th day, and by 77.4% on the 35th day. Compared with the tumor model control group without drug, the tumor weight of the CKM drug group was reduced by 76.3%, which had a significant effect of reducing tumor volume and preventing cancer cell spread and metastasis. The use of CKM in the treatment of cancer model nude mice showed normal appetite, normal spirit, normal sleep, and normal body weight, without signs of pain and discomfort, indicating that CKM can significantly improve the quality of life and survival of liver cancer nude mice.

[0071] 本專利發明在一個實施例中顯示了 CKM大鼠用藥組超大劑量經皮膚外用一次 The acute toxicity and safety experiment showed that compared with the normal control group, the biochemical indicators of the internal organs and tissues of the CKM ultra-large dose drug group were not abnormal, and there was no difference in body weight between the groups. There was no skin allergy and skin irritation phenomenon, indicating that CKM is safe, non-toxic, and has no side effects.

[0072] 本專利發明在一個實施例中 CKM用藥組經皮外用於豚鼠 30日亞急毒性安全 The experiment showed that compared with the control group, after 30 days of transdermal use of CKM, there were no abnormalities in the internal organs and biochemical indicators of guinea pigs, and there were no skin allergy and irritation phenomena, indicating that CKM is safe, non-toxic, and has no adverse side effects and no damage to normal cells.

[0073] 本專利發明在一個實施例中 CKM經皮膚外用方式治療與改善人體末期胸腺 Cancer, indicating that it also has the effect of inhibiting the proliferation and spread of cancer cells, eliminating effusion, inhibiting tumors, eliminating postoperative sequelae, and improving the quality of life of patients with end-stage thymus cancer.

[0074] 本專利發明中所述 CKM與任何物質稀釋或組合可成為不同形態以不同劑型皮 The transdermal use or injection can be used for cancer including but not limited to liver cancer. In one embodiment, the composition of CKM includes eucalyptus globules extract and canarium extract. The embodiment is composed of (A) CKM, (B) eucalyptus extract, (C) canarium extract, and each extract can be obtained by chromatography, separation, supercritical extraction, etc.

[0075] In one embodiment of the present invention, the combination of (A) CKM, (B) eucalyptus extract, and (C) canarium extract is mixed in a proportion range, and the mixed and shaken materials are placed at 0°C or above for 60 minutes before use.

[0076] Embodiment

[0077] Uncontrolled cell variation, proliferation, spread and metastasis are common characteristics of all cancers and malignant tumors. Liver cancer is characterized by rapid spread of cancer cells and rapid tumor proliferation due to delayed detection. Most liver cancer is found in the terminal stage, and it is the most difficult cancer to overcome globally. Liver cancer patients have a high mortality rate due to rapid tumor growth. Rapid spread of cancer cells and cancer metastasis cause liver cancer patients to have an average survival period of only 6 months. Most patients with advanced liver cancer may temporarily control the spread of cancer cells and proliferation, but cancer recurrence or cancer cell metastasis occurs within 5 years. Literature shows that the 5-year survival rate of hepatocellular carcinoma patients is only about 12.1%. Literature shows that the median survival time of liver cancer patients treated with the most commonly used first-line drugs such as regorafenib and sorafenib is only 13.6 and 12.3 months (50% of patients survive to this time), respectively. The present invention believes that restoring the normal immune regulation mechanism of cancer patients, restoring cell function, killing cancer cells, and inhibiting the growth of malignant tumors can truly produce a fundamental therapeutic effect.

[0078] 本專利發明以 CKM皮膚外用及注射方式用於治療包括而不限於肝癌的癌症治 The therapeutic effect is obvious. In one embodiment, (A) CKM, (B) eucalyptus extract, and (C) olive extract are combined in a range of ratios. All substances can be obtained by chromatography, separation, supercritical extraction, etc. The combined percentage ratio is (A) CKM 5-30: (B) 7-35: (C) 35-90. The effective ratio range is (A) CKM 2.5-25: (B) 4-30: (C) 45-85. The optimal ratio range is (A) CKM 1-25: (B) 3-25: (C) 30-80.

[0079] In some annexes of the present invention, CKM is named "SDTL-liver cancer" or "SDTL-cancer killer" or "Chengtian liquid cancer killer" in different annexes at different stages of the research process. Although the name of CKM is not the same in all annexes, it is the same substance CKM.

[0080] Example 1: (see Annex 1. Transdermal administration of liver cancer in humans)

[0081] 在本專利發明的實施例一中 CKM（曾名"SDTL-肝癌”）經皮膚外用治療人 Clinical observation reports of cancer patients show that the tumor suppression and pain relief effect on endocrine organ liver cancer patients in the terminal stage is significant, significantly reducing tumor size and improving appetite, improving mental and sleep and body weight, and improving the quality of life. The alpha-fetal protein (AFP) index of a liver cancer patient with a large tumor of 13x9x17cm was reduced from 93611ng / ml to 1072ng / ml, with a 3-month reduction of 87.324%, and the survival period was extended by more than 10 years (no further follow-up after 10 years).

[0082] 在實施例一中病人陳 x英，女 51歲，入院日期 1997年 1月 2×日家庭醫學Case file No. B058-2x, abdominal CT scan showed a liver tumor in the right lower rib position, the tumor volume was 13x9x17cm, which was a giant liver tumor, with necrosis in the middle position, and different sizes of DAUTER small nodular tissues were found in the left and right lower ribs, showing a spread of the disease.

[0083] 在實施例一中病人 1997年 1月 22日 AFP 93611 ng / ml（采血日期為 1月 16 On the 22nd, at 13:00, the patient applied CKM (0.4 mL) to the skin of the liver area for 5 minutes, and the pain disappeared and the fatigue was significantly reduced. The patient had poor appetite, but at 18:00 that evening, he was able to eat 2 bowls of rice (the patient had complained of poor appetite for nearly half a year, and his weight had dropped significantly due to his inability to eat). At 19:00 that evening, he used CKM again (0.4 mL) and went out to play for nearly 3 hours without feeling tired, with a good spirit and a big appetite for snacks. The patient was overjoyed and said he hadn't been so happy in half a year. He had no pain throughout the day and night, and slept very well until dawn.

[0084] 在實施例一中病人 1997年 1月 23日檢驗報告顯示 AFP 66676 ng / ml， HBsAg was positive, and the GI doctor advised against surgery. On January 29, the patient underwent TAE antibiotic treatment. After 3 days of TAE, the patient developed a fever, and GOP, GPT, and KDII increased. On February 5, the fever subsided, and GOT, GPT, and LDH levels decreased. The patient had increased heart noises, and a cardiac examination showed a severe MR. The attending physician advised reducing salt intake and adding a low-dose diuretic and ACEI. The attending physician did not recommend surgery, and the patient was discharged after the condition stabilized, to be followed up in the outpatient department.

[0085] 在實施例一中病人 1997年 2月 14日（采血日期為 2月 10日）AFP 22478 ng / ml. After using CKM on the skin on January 22, the patient slept well, had a good appetite, and was in good spirits. His face was red and full of energy, and he had no pain. His weight increased by 5 kg, but the patient claimed that he often forgot to use "SDTL-liver cancer" because he felt good.

[0086] 在實施例一中病人 1997年 4月 23日（采血日期為 4月 17日）AFP 1072 ng / ml. By April 23, the patient slept well, had a good appetite, and was in good spirits. However, he claimed that if he reduced the use of CKM to only 1-2 times a day (originally 3-4 times a day), he felt slightly tired, his appetite decreased, and his sleep was unstable, and his condition seemed to worsen. However, if he continued to use it, his condition stabilized and improved significantly.

[0087] 在 10年後（2007年）間接追訪瞭解患者狀況患者巨大肝腫瘤早己消失且生 The patient's quality of life was like that of a normal person, still alive in the world. Due to various reasons, the patient did not continue to follow up.

[0088] Example 2: (see Annex 2. Animal liver cancer experiment using percutaneous and injection)

[0089] 在本專利發明的實施例二中 CKM（曾名"SDTL-殺癌”）藥物在動物裸鼠肝In the cancer experiment, whether it is used externally on the skin or injected into the tumor, it has a significant and rapid targeting effect on the tumor cells of the liver cancer. The 50uL used externally on the skin reduced the size of the large liver cancer tumor (1.8cm3) by 63.2% in just 12 days, by 70% in 26 days, and by 77.4% in 35 days. Compared with the control group without CKM, the CKM ("SDTL-killer") drug group reduced the weight of the tumor by 76.3%, showing that CKM has a significant and rapid inhibitory effect on tumor growth and tumor reduction without affecting the quality of life and activity of the patient.

[0090] 在實施例二中 CKM（"SDTL-殺癌”）藥物在動物裸鼠實驗中抑制肝癌生長 The single-blind study showed that the A, B, and C creams were applied to the tumor site of each nude mouse with liver cancer, and after 12 days, it was found that the tumor in the C group was significantly smaller than that in the A and B groups. After 21 days of skin application, the tumors in the A and B groups were significantly larger than that in the C group. In order to observe the effect of different drug administration methods on the tumor and improve the effectiveness of the drug, the skin application of the cream was changed to intraperitoneal injection of 160uL of plant oil containing the CKM ("SDTL-killer") drug every day, and after 24 days, it was changed to intraperitoneal injection of 100ul of plant oil containing the CKM drug every day.

[0091] 在實施例二中第 30天時因經計算 A組腫瘤大小已超過體重的 10%，故殺 A The average weight of the tumors in the A group was 1.38 grams (0.91-1.89 grams), while the tumors in the C group were significantly smaller than those in the A and B groups.

[0092] 在實施例二中第 35天時，同時殺 B、C兩組所有老鼠以分析與比較腫瘤大 The average weight of the tumors in the B group was 1.67 grams (1.03-2.64 grams), and the average weight of the tumors in the C group was 0.40 grams (0.19-0.72 grams). The tumor in the B group was 4.175 times larger than that in the C group, and there was a significant difference between the two groups.

[0093] 在實施例二中實驗結束比較與統計顯示 A組老鼠第 30日腫瘤大小超體重 10% The average weight of the tumors in the A group was 1.38 grams (0.91-1.89 grams), while the tumors in the B group were significantly larger than those in the C group.

[0094] The results of Example Two revealed that the A group contained a plant extract, the B group was a blank control group, and the C group used the CKM ("SDTL-killer") drug. The tumor in the A group was 3.45 times larger than that in the C group, and the tumor in the B group was 4.175 times larger than that in the C group, showing that the CKM drug has a strong therapeutic activity in improving immunity, inhibiting liver cancer growth, eliminating tumors, preventing tumor enlargement, and preventing cancer cell metastasis, with a very good clinical application prospect.

[0095] 在實施例二中實驗結果顯示 CKM能強力抑制癌細胞生長及具顯著消瘤，能阻It can stop liver cancer cell metastasis, reduce ascites, improve liver function, has no toxic side effects, can significantly inhibit tumor metastasis and expansion, and can significantly improve the quality of life.

[0096] In Example Two, since the human body has an immune response ability thousands of times stronger than that of immunodeficient mice, it is predicted that the therapeutic effect of CKM in humans is much higher than that of immunodeficient experimental mice.

[0097] Example Three: (See Appendix Three. Animal acute toxicity safety test of transdermal drug)

[0098] 在本專利發明的實施例三經國際公証機構 SGS動物實驗中，將 CKM（曾名 "Chengtian Liquid Kailings" was used transdermally in a one-time super large dose. In the skin acute toxicity test, 40 adult rats, half male and half female, weighing 200-300 grams, were selected. The hair area of 3 cm x 4 cm on both sides of the dorsal spine was shaved, and CKM was applied to the depilated area at a dose of 2500 mg / kg (far exceeding the therapeutic dose for humans). After 24 hours of fixation, the remaining material was washed with warm water, and observations were made for 14 days.

[0099] 在實施例三中經皮膚一次性超大劑量使用 CKM觀察，觀察內容包括皮膚、與 Hair and behavior and movement changes, diet status, and limb activity were observed, and t-test analysis was performed using SPSS for windows 10.0 software.

[0100] 在實施例三中結果顯示 14日觀察期內 CKM試驗組和對照組動物的行為活動 All animals showed normal behavior, and there were no abnormalities in food intake and feces. No skin erythema or edema occurred, and the animals grew normally during the observation period. No animals died, and there was no difference in body weight between the groups (p>0.05).

[0101] Table 1: Body weight changes in FIG. 5.

[0102] 在實施例三中結果顯示受試物 CKM的大鼠經皮急性毒性實驗最大耐受量＞ 2500 mg / kg, far exceeding the optimal therapeutic dose for humans, the results of the transdermal acute toxicity test on rats showed that CKM was actually non-toxic.

[0103] 實施例四：（見附件四.經皮膚用藥動物 30日亞急毒安全性實驗）

[0104] 在本專利發明實施例四中經 SGS國際公証機構檢測 CKM（時名"承天液克癌 Example Four: (See Appendix Four. 30-day subacute toxicity safety test of transdermal drug)

[0105] 在實施例四中將 CKM均勻塗抹於豚鼠脫毛區，塗抹後用油紙和紗布覆蓋紙膠 The animals were fixed with tape, and CKM was applied daily for 6 hours before removing the covering. The animals were observed and their health status and behavior changes, including skin and systemic symptoms, appetite, food intake, and activity, were recorded daily for 30 days. The animals were weighed before the experiment, on the first day of use, and every week thereafter.

[0106] At the end of Example Four, all animals were bled for blood analysis and internal organ testing. The testing indicators and units are shown in Table Two.

[0107] 在實施例四中，表二為血液檢測指標，如 FIG. 6。

[0108] 在實施例四中，表三為血液生化檢查項目，如 FIG. 7。

[0109] 在實施例四中，表四為血液生化檢測，如 FIG. 8。

[0110] 在實施例四中，表五為動物食物消耗量，如 FIG. 9。

[0111] 在實施例四中，表六為解剖後臟器係數，如 FIG. 10。

[0112] 在實施例四中結果顯示 CKM（"承天液克癌靈”）經皮膚外用高、低劑量組Compared with the control group, there was no significant change in the organs such as heart, liver, spleen, stomach and other biochemical indicators between groups, and there was no significant difference in body weight. After 30 days of daily 1 mL or 2 mL dose of transdermal administration, guinea pigs showed no abnormal reactions related to CKM.

[0113] Example five: (see annex five. Detection of pesticide residues)

[0114] 在本專利發明的實施例五中經 SGS國際公証機構檢測 CKM（時名"承天液克 There is no pesticide residue in "Cancer Ling".

[0115] Example six: (see annex six. Transdermal administration of human thymus cancer patients)

[0116] 在本專利發明的實施例六中病患馮 XX，女 66歲有高血壓、糖尿病史超過 10 In 2023, he took 500mcg of folic acid, 5mg of blood pressure-lowering medicine, and 20mg of cholesterol-lowering medicine every day. After receiving the third dose of the new crown vaccine (Pfizer) in May, he experienced heart pain but no other symptoms. He was infected with the new crown virus (nucleic acid test positive) but recovered naturally.

[0117] 在實施例六中患者 2023年 12月因長期受腰痛、咳嗽、氣喘、氣促、胸悶、 He was tired and went to a XX public hospital in the Hong Kong government for a blood test, which diagnosed him with a filterable virus herpes zoster. After taking medicine for more than 10 days, the herpes zoster healed. However, cancer cells were found in his blood, and he was suspected of having lung cancer. He had a lung fluid test for lung cancer-related pathology on the same day, and scheduled a further Chest X-ray examination. Because the examination was scheduled too long, the patient was willing to pay for a Chest X-ray examination at the hospital's recommended medical diagnosis center.

[0118] 在實施例六中患者 2023年 12月 28日至公立醫院推介博×醫學診斷中心 HKAIHong Kong Advanced Imaging performed a chest X-ray examination. The next day, the chest X-ray report showed that the patient had a right pleural effusion with a thickness of 6.83 cm, a posterior pleural mass of 4.3 x 2.1 x 5.1 cm, surrounded by some smaller nodular pleural thickening, a 1.19 x 1.27 x 1.44 cm contrast proliferative lesion subpleural nodule in the right anterior lower middle lobe, 0.21 cm and 0.43 cm non-specific nodules in the right anterior middle lobe, collapsed consolidation of the right lower lobe, and calcification of the thoracic aorta and coronary arteries, suggesting atherosclerosis. The preliminary diagnosis was stage 4 thymic carcinoma. (Rightpleural effusion and measures 6.83 cm in thickness. There is a 4.3 x 2.1 x 5.1 cm pleural mass posteriorly with some smaller nodular pleural thickening around. Tumor infection. 1.19 x 1.27x1.44 cm contrast enhancing subpleural nodule in anterior inferior middle lobe of right lung. It is suspicious of tumor. 0.21cm and 0.43 cm non-specific nodules in anterior middle lobe of right lung. Collapse consolidation in lower lobe of right lung. Calcification noted at the thoracic aorta and coronary arteries, Because of the suspicion of brain metastasis (because thymic carcinoma has the potential to metastasize to the brain), additional related tests were arranged.

[0119] 在實施例六中患者 2024年 1月 24日檢查結果顯示未發現癌細胞顱內轉移， No evidence of infarction or cerebral edema was found, no hemorrhage or local masses were detected, and no abnormal extraaxial aggregates were found. On the same day, after being referred by another patient and at the patient's request, the patient began topical CKM (then called "SDTL-Cancer Killer") treatment, applying 0.4 ml to the chest skin three times daily. Following use, the patient's appetite significantly improved, and his cough and chest tightness were alleviated.

[0120] 在實施例六中患者 2024年 1月 26日接醫院通知將安排做 8次 Carboplatinand Pemetrexed intravenous chemotherapy. After the first chemotherapy, there were pulmonary hydrops, stomach discomfort, and a foreign body pressing sensation, and there were vomiting and anorexia, and the patient was significantly more tired and started to lose hair, and when sleeping on the side, breathing was very uncomfortable and easy to wheeze. Within 30 minutes after using CKM on the same day, the discomfort disappeared, and the patient continued to use CKM externally on the skin, 0.4 mL each time.

[0121] 在實施例六中患者 2024年 2月 8日醫院再次確認患者為肺腺癌 4期，右肺積 Water, cancer index 9.2, PD-L1 index 40, blood oxygen saturation 97-98, body weight 47-48 kg. On February 22, 2024, two days after the second chemotherapy, there was mild constipation, and walking upstairs and fast walking was more difficult to breathe, and the back was tight, and when sleeping on the right side, breathing was not smooth. All the discomfort disappeared on the third day of continuing to use CKM externally on the skin.

[0122] 在實施例六中患者 2024年 3月 22日覆診時癌指數有輕微改善(9.6降至 9.2), and pulmonary hydrops needed a computer scan on April 8. During chemotherapy, the patient insisted on using CKM externally on the skin, 0.4 mL each time, 2 times a day, and the stomach was quite good, and the body weight did not decrease, and the spirit was good, and the sleep was good.

[0123] 在實施例六中患者 2024年 4月 7日自訴在使用 CKM後明顯能減少化療副作用 and the sequelae were significantly improved, the body condition and sleep were improved, and the cancer index had gradually decreased from 9.6 to 5.7. Thereafter, chemotherapy was performed once every 4 weeks, and on April 23, 2024, the tumor was controlled without enlargement, and there was no cancer cell spread and metastasis phenomenon, and the patient's condition was stable. The patient reported that the appetite was still good, and the breathing was smooth and basically without wheezing phenomenon, and the body weight did not decrease, and the patient felt quite good. The patient stopped using CKM after using CKM for 90 days.

[0124] 在實施例六中患者停止使用 CKM後 10個月的 2025年 2月 14日，追訪患者 It was learned that a total of 17 times of chemotherapy had been performed. Since April 23, 2024, after using CKM, the patient's condition was stable, there was no cough and wheezing, the appetite was still good, and the body weight was also almost the same, the tumor size did not change, and there was no cancer cell spread and metastasis phenomenon, and the condition was stable, but it was very obvious that after using CKM, the side effects of each chemotherapy were obvious. After chemotherapy, symptoms such as mouth dryness, chest tightness, and discomfort gradually disappeared for about at least one week.

[0125] 在實施例六中顯示了 CKM經皮膚外用方式治療與改善四期胸腺癌的狀況，顯 It was shown that CKM had the effects of eliminating hydrops, inhibiting tumors, inhibiting cancer cells, eliminating sequelae after chemotherapy, and improving the quality of life for patients with non-periodic thymus lung cancer.

[0126] Although variable and dependent on application, the following examples are provided for using the methods or compositions disclosed herein. Those skilled in the art will recognize that some steps can be performed in any practical order to produce a composition or compound in the desired use.

[0127] The above description and drawings are only illustrative of the application and do not limit the present application. While the specification is described in relation to certain implementations or examples, numerous details are set forth for the purpose of explanation only. Further, the foregoing description is not intended to limit the application to the form described herein. Accordingly, while the specification is described with or in terms of certain implementations or examples, the application should not be construed to be limited to the implementations or examples set forth herein. Rather, the scope of the application should be determined by reference to the claims. For example, although a particular feature or aspect of the application can have been disclosed with respect to only one of the implementations or examples, such feature or aspect can be combined with one or more other features or aspects of the other implementations or examples as a combination of the features and aspects are within the scope and spirit of the application. Further, to those skilled in the art, other implementations or examples will readily occur, which are likewise intended to be encompassed within the scope and spirit of the application.

[0128] The above description is illustrative and is not restrictive. Many variations of the application will become apparent to those skilled in the art upon review of the disclosure. The scope of the application should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope or equivalents.

[0129] One or more features of any implementation can be used in combination with one or more features of any other implementation without departing from the scope of the application. The terms "a," "an," or "one" are intended to refer to one or more unless indicated otherwise. The term "and / or" is intended to represent any of the possibilities that the term can represent, unless otherwise indicated. The term "comprising" is intended to mean including but not limited to, unless otherwise indicated.

[0130] While the disclosure can be susceptible to various modifications and alternative forms, the disclosure is shown by way of example in the drawings and description herein in which:

[0131] The present disclosure provides a solution to the long-felt need described above. In particular, aspects of the present application overcome the reliance on current There is a need for a way to treat and improve cancer using oral medications, either natural or non-natural chemicals or compounds and formulations, to help restore the quality of life and mobility of cancer patients, to eliminate pain, and to prolong survival.

[0132] Further advantages and modifications of the above described components and methods can readily occur to those skilled in the art.

[0133] The disclosure is therefore to be considered in all respects as illustrative and not restrictive, since the scope of the disclosure will be measured by the appended claims and equivalents thereof.

Claims

Claims:

1. A carbon-containing small micromolecule compound for external application on the skin and injection to treat organic cancer, comprising an extract of the plant clove (Eugenia caryophyllata Thunb or Syzygium aromaticum or Syringaoblata Lindl), referred to as CKM.

2. According to claim 1 of the patent application, the components of the clove extract CKM for external application or injection for the treatment of visceral organic cancer include eugenol (Eugenol.C10H12O2) and syringylalcohol (syringylalcohol.C15H26O).

3. According to claim 2 of the patent application, the CKM can kill liver cancer cells through skin application and injection, treat liver tumors and inhibit the spread of cancer cells, prevent cancer cell metastasis and significantly shrink solid cancer tumors.

4. According to claim 3 of the patent application, the CKM can be applied externally on the skin and injected to treat cancers including liver cancer. It has the effects of inhibiting the proliferation of cancer tumors and significantly killing cancer cells, preventing the spread of cancer cells and eliminating tumors. It can prevent the metastasis of cancer cells without harming normal cells, and has the function of promoting the recovery of normal immunity without side effects.

5. According to claim 3 of the patent application, the CKM has the functional effect of treating organic liver cancer and other cancers, and can alleviate and eliminate the sequelae syndrome of chemotherapy.

6. According to claim 3 of the patent application, the CKM can promote the normal immune mechanism and immunity recovery of cancer patients, improve the appetite, weight and mental state of patients, eliminate fatigue and improve sleep, and has the characteristics of rapid therapeutic effect and obvious biological effect.

7. According to claim 3 of the patent application, the CKM can be combined with other solvents and substances and then applied externally to the skin or injected to treat organic cancers including internal organs.

8. According to claim 3 of the patent application, the CKM can be diluted or combined with any other ingredients such as solvents, compounds, etc., and then applied externally through the skin or directly injected to treat organic cancers including visceral cancers. The ratio is preferably 5:5, 4:6 is more preferred, and the optimal ratio range is 0.5~3.5:6.5~8.

9. According to claim 3 of the patent application, the reason why the CKM skin topical application and injection are suitable for the treatment of visceral organic cancer and malignant tumors is that it avoids decomposition by oral digestive enzymes and gastric acid, avoids the first-pass effect of the liver, and physiological barriers such as the blood-brain and kidney organs, and also avoids the adverse side effects caused by oral administration. It is a direct and rapid external application method for the treatment of visceral organic cancer, with less damage to normal cells and organs and few side effects.

10. According to claim 3 of the patent application, the CKM can be used externally through the skin or by injection alone, and can also be used in combination with other molecules and substances in liquid, solid and gaseous forms in different proportions by combining, blending, fusion, chelation, coupling and recombination. Its forms include ointments, emulsions, sprays, ointments, patches, solid preparations, etc.

11. According to claim 3 of the patent application, CKM's small molecular weight and large surface area are the first element; its topical use on the skin is the second element; its ability to be mixed with other solvents in appropriate proportions is the third element; and its fat solubility is the fourth element. Injection is an extension method and the fifth element; the ability to be used in combination with any other substance is the sixth element. These six elements constitute the essential components of CKM topical skin cancer treatment.

12. According to claim 3 of the patent application, the CKM skin topical application is more effective for treating severe pain caused by cancer than morphine injection. CKM has a faster onset time, a longer analgesic effect, and a more significant analgesic effect than morphine injection. It can improve and eliminate the physical discomfort sequelae and adverse reactions caused by chemical drugs and therapies.

13. According to item 3 of the patent application claim, the CKM and other extracts in the invention method of this patent can be obtained by boiling and concentration, distillation and pressing, evaporation and freezing, chromatography and separation, supercritical, high-pressure spraying, artificial synthesis and other different methods.

14. According to claim 3 of the patent application, CKM and its embodiments can be applied externally through the skin or directly injected to treat cancers including liver cancer, and have the effects of inhibiting and eliminating tumors, killing cancer cells, preventing cancer cell proliferation, preventing cancer cell spread and metastasis, and shrinking malignant tumors. They can reduce the specific index of cancer markers and reduce the alpha-fetoprotein AFP value.

15. According to claim 14 of the patent application, the invention comprises a combination of (A) CKM, (B) Eucalyptus globules extract, (C) Olive Canarium extract, and the like. In the embodiment, the ratio of (A) CKM, (B) Eucalyptus globules extract, and (C) Olive Canarium extract is: (A) CKM 5-30: (B) 7-35: (C) 35-90. The effective ratio range is (A) CKM 2.5-25: (B) 4-30: (C) 45-85. The optimal ratio range is (A) CKM 1-25: (B) 3-25: (C) 30-80.

Images